Drawing for REAL AKG MATRAXOL - ARGININE AKG TECHNOLOGY

USPTO serial 78586868

REAL AKG MATRAXOL - ARGININE AKG TECHNOLOGY

Reviewed by CopyMark Law Group

Reg. 3063569Status 710
Filing date
Status date
Registration date
Feb 28, 2006
Examiner
BESCH, JAY C
Law office
TMEG LAW OFFICE 108

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with REAL AKG MATRAXOL - ARGININE AKG TECHNOLOGY?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Amy J. Benjamin

Amy J. Benjamin Benjamin Law PC163 Third AvenueSuite 284New York, NY 10003

Goods and services

ClassDescriptionStatusFirst use
001chemicals for use in the manufacture of cosmetics, pharmaceuticals, beverages and nutritional supplementsSECTION 8 - CANCELLEDJun 2, 2004
005Dietary supplement, nutritional supplement, and pharmaceutical supplement, proven to be safe and effective in the delivery, availability, modulation, transport and uptake of L-arginine, helping L-arginine as a conjugate cross the blood brain barrier, reducing cardiovascular risk factors, stimulating an increasing the body's production of anti-aging hormones, retarding of aging process and increasing nitric oxide production by endothelial cellsSECTION 8 - CANCELLEDJun 2, 2004

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 5, 2012C8..CANCELLED SEC. 8 (6-YR)—
Jan 26, 2009ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jan 26, 2009REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jun 4, 2008ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Mar 21, 2006UNDCUNDELIVERABLE MAIL - COURTESY COPY MAILED—
Mar 13, 2006MAILPAPER RECEIVED—
Feb 28, 2006R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jan 27, 2006DOCKASSIGNED TO EXAMINER—
Dec 6, 2005PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 16, 2005NPUBNOTICE OF PUBLICATION—
Oct 13, 2005PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Oct 7, 2005ALIEASSIGNED TO LIE—
Sep 30, 2005CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Sep 30, 2005GNEAEXAMINERS AMENDMENT E-MAILED—
Sep 30, 2005CNEAEXAMINERS AMENDMENT -WRITTEN—
Sep 30, 2005DOCKASSIGNED TO EXAMINER—
Apr 25, 2005AMPXPRELIMINARY/VOLUNTARY AMENDMENT - ENTERED—
Apr 25, 2005PARITEAS VOLUNTARY AMENDMENT RECEIVED—
Mar 18, 2005NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance